Inherited or genetic heart disorders, mostly known as Hypertrophic cardiomyopathy (HCM) in medical term, is a condition ...
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary ...
BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...
Shared decision-making forms an increasingly important part of the expert consultation for athletes with genetic heart disease. 1–3, 5 Shared decision-making involves a personalized discussion and ...
Medical Xpress on MSN7d
Why Black Mothers In Low-Income Neighborhoods Have Higher Risks Of Heart DiseaseLiving in a disadvantaged neighborhood contributes to a rare form of heart failure known as peripartum cardiomyopathy, a potentially deadly disease that disproportionately affects Black mothers.
Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...
Alnylam has the FDA approval it sought for Amvuttra in a form of cardiomyopathy associated with rare disease ATTR amyloidosis ...
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...
Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback